Nucleic Acid Based Gene Therapy Market Revenue Growth Forecast To Reach $1.43 Billion By 2030 At 10.4% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Anticipated Rise In Market Value Of The Nucleic Acid Based Gene Therapy Market During The Forecast Period?
The nucleic acid based gene therapy market size has experienced rapid expansion in recent years. This market is projected to expand from $0.88 billion in 2025 to $0.97 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.2%. The historical growth can be credited to advancements in molecular biology research, an enhanced understanding of genetic disease mechanisms, the proliferation of clinical trials for gene therapies, increasing investment in biotechnology research, and initial regulatory approvals for nucleic acid therapies.
The nucleic acid based gene therapy market is projected to experience substantial expansion in the coming years. By 2030, it is anticipated to reach a value of $1.44 billion, growing at a compound annual growth rate (CAGR) of 10.4%. This projected growth during the forecast period can be linked to factors such as the increasing integration of CRISPR-based treatments, a heightened demand for rare disease therapies, the expansion of gene therapy manufacturing facilities, an elevated focus on personalized oncology treatments, and a rise in both public and private investment in genetic medicine. Significant trends for the forecast period include the growing adoption of RNA-based therapeutics, the increasing utilization of viral and non-viral gene delivery systems, an intensified focus on targeted gene editing technologies, the broadening of personalized genetic therapies, and a strengthened emphasis on precision medicine applications.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Primary Drivers Are Impacting The Nucleic Acid Based Gene Therapy Market Growth?
The nucleic acid based gene therapy market is anticipated to expand due to increasing financial contributions from governments and corporations. This support includes monetary investments, grants, or subsidies from public and private institutions, aimed at advancing the research, development, and commercialization of these therapies. The heightened financial backing is attributed to a global focus on finding treatments for rare and genetic diseases that currently lack effective cures. Specifically, government funding for nucleic-acid–based gene therapy speeds up progress by supplying essential resources for research, clinical trials, and infrastructure, directly promoting innovation and the transformation into effective treatments. As an illustration, the U.S. National Institutes of Health, a U.S.-based federal health research agency, reported in July 2023 an allocation of over $140 million to accelerate genome editing approaches, including CRISPR and other nucleic acid technologies, for rare neurological and blood disorders. This sum signifies a notable increase compared to the $92 million in annual funding from 2022. Ultimately, the increasing financial support from both governmental bodies and private companies is propelling the growth of the nucleic acid based gene therapy market.
What Are The Key Segment Divisions In The Nucleic Acid Based Gene Therapy Market Segment Structure?
The nucleic acid based gene therapy market covered in this report is segmented –
1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies
2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases
3) By End User: Hospitals And Clinics, Academic And Research Institutes
Subsegments:
1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)
2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies
3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)
4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs
5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes
6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers
7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)
Which Trends Are Shaping Growth In The Nucleic Acid Based Gene Therapy Market?
Major companies in the nucleic acid-based gene therapy market are increasingly focusing on personalized, autologous stem-cell therapies, such as infusions of genetically modified hematopoietic stem cells, to address rare inherited diseases. Autologous therapies involve taking a patient’s own stem cells, genetically correcting them, and then re-infusing them to restore lost biochemical function. For example, in March 2024, Orchard Therapeutics, a US-based pharmaceutical company, announced that Lenmeldy (atidarsagene autotemcel) had been approved by the U.S. Food and Drug Administration for children diagnosed with metachromatic leukodystrophy (MLD). Lenmeldy employs the patient’s own hematopoietic stem cells, which are genetically modified to express a functional ARSA gene, thereby allowing for enzyme restoration within the nervous system. This successful regulatory outcome demonstrates how firms can commercialize sophisticated, autologous gene therapies even when faced with high manufacturing expenditures.
Which Organizations Are Engaged In The Nucleic Acid Based Gene Therapy Market?
Major companies operating in the nucleic acid based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.
Get The Full Nucleic Acid Based Gene Therapy Market Report:
Which Region Dominates The Nucleic Acid Based Gene Therapy Market By Market Share?
North America was the largest region in the nucleic acid-based gene therapy market in 2025. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Nucleic Acid Based Gene Therapy Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Nucleic Acid Based Gene Therapy Market 2026, By The Business Research Company
Genes Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Cell And Gene Therapy Clinical Trial Services Market Report 2026
Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
